Researchers engineered a nanobody-conjugated liposome (A5-LNP-DOX) that targets CD155 and delivers doxorubicin directly to ...

China’s National Medical Products Administration gave the green light to Simcere Pharmaceutical Group Ltd.’s Enzeshu (suvemcitug) for treating recurrent ovarian cancer, fallopian tube cancer, or ...

The buyer in this case is Alembic’s US subsidiary, Alembic Pharmaceuticals Inc., which will take over full ownership of Utility.

The shares of this leading pharmaceutical company are in focus after the company secured the USFDA's approval for its key ...

Alembic Pharmaceuticals share surged after the company received final approval from the USFDA for its ANDA for Doxorubicin Hydrochloride Liposome Injection in two dosage strength.

According to IQVIA, the market for Doxorubicin Hydrochloride Liposome Injection is estimated at $29 million for the twelve months ending March 2025.

Alembic Pharmaceuticals surged 10.92% to Rs 1,078 after the company received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for ...

The company received USFDA approval for Doxorubicin Hydrochloride Injection, which will be use for the treatment of Ovarian Cancer, AIDS-Related Kaposi’s Sarcoma, and Multiple Myeloma.

Pegylated liposomal doxorubicin (PLD) is frequently administered in later lines of treatment, usually when no other active drugs are available, even in first-line (1L) AC pre-treated patients (pts).

ETCTN 10563: A phase I study of peposertib and liposomal doxorubicin for advanced or metastatic leiomyosarcoma and other sarcomas.

The Liposomal Doxorubicin Market is estimated to be valued at USD 1,281.3 million in 2024. Demand is predicted to rise at a CAGR of 6.3% from 2024 to 2034. The market is anticipated to reach USD 2,367 ...

Global pharma major Lupin Limited (Lupin) announced the launch of doxorubicin hydrochloride liposome injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials in the United States, ...